A Multi-Center, Open-Label, Single-Arm, Phase 2 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Vabomere (Meropenem-Vaborbactam) In The Treatment Of Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Latest Information Update: 06 Jul 2026
At a glance
- Drugs Meropenem/vaborbactam (Primary)
- Indications Pyelonephritis; Urinary tract infections
- Focus Adverse reactions
- Sponsors Rempex Pharmaceuticals
Most Recent Events
- 03 Jun 2026 Status changed from recruiting to active, no longer recruiting.
- 02 May 2025 Planned initiation date changed from 1 Apr 2025 to 1 May 2025.
- 17 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.